Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 6, 2022; 10(25): 8863-8871
Published online Sep 6, 2022. doi: 10.12998/wjcc.v10.i25.8863
Published online Sep 6, 2022. doi: 10.12998/wjcc.v10.i25.8863
Evaluation of the prognostic nutritional index for the prognosis of Chinese patients with high/extremely high-risk prostate cancer after radical prostatectomy
Fan Yang, Min Pan, Jin Nie, Fan Xiao, Yuan Zhang, Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Author contributions: Zhang Y conceptualized and designed this study; Yang F collected the data and drafted the manuscript; Pan M and Nie J analyzed and interpreted the data; Xiao F and Zhang Y were responsible for critically revising the manuscript for important intellectual content; all authors approved the final version for submission.
Institutional review board statement: This study was approved by the Ethics Committee of the Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.
Informed consent statement: The data used in this study were not involved in the patients’ privacy information, so the informed consent was waived by the Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yuan Zhang, BSc, Chief Physician, Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan 430030, Hubei Province, China. tjzy2781@163.com
Received: April 19, 2022
Peer-review started: April 19, 2022
First decision: May 11, 2022
Revised: May 22, 2022
Accepted: July 29, 2022
Article in press: July 29, 2022
Published online: September 6, 2022
Processing time: 128 Days and 23.5 Hours
Peer-review started: April 19, 2022
First decision: May 11, 2022
Revised: May 22, 2022
Accepted: July 29, 2022
Article in press: July 29, 2022
Published online: September 6, 2022
Processing time: 128 Days and 23.5 Hours
Core Tip
Core Tip: Radical prostatectomy is the main treatment for prostate cancer (PCa). However, the incidence of postoperative complications and tumor progression remains high, and patients are highly prone to recurrence or metastasis. Therefore, it is crucial to identify effective prognostic biomarkers. The pro